Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $62.71M. The enterprise value is -$22.85M.

Inovio Pharmaceuticals has 36,673,466 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.14%.

The current PE Ratio of Inovio Pharmaceuticals is -0.46. Inovio Pharmaceuticals’s PEG ratio is 0.01.

In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.

In the last 12 months, operating cash flow was -84.43B and capital expenditures 0.00, giving a free cash flow of -84.43B billion.

Inovio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 17.32%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is 518.52, with an EV/FCF ratio of 0.52.

Inovio Pharmaceuticals has $94.11M in cash and marketable securities with ― in debt, giving a net cash position of -$82.25M billion.

Gross margin is -629.42%, with operating margin of -51616.91%, and net profit margin of -49254.27%.

The average price target for Inovio Pharmaceuticals is $6.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy